Board of Directors
Chairman of the Board
Chairman of the Board since 2018. Chairman of the Remuneration Committee and member of the Audit Committee.
MBA, US.CPA. He served as a Board Member in BioInvent between 2016–2017. He was CFO and member of the board of Crucell NV from 1998 to 2011 and has held senior executive positions at Royal Boskalis N.V., GE Capital and Continental Can Company. Born 1958.
Other board appointments: Board member in Zealand Pharma A/S, Oncolytics Biotech Inc. and member of the Investment Advisory Council in Karmijn Kapitaal Investments.
Member of the Board since 2013. M.Sc. in Molecular and Functional biology. Senior Research Engineer. Born 1959.
Other board appointments: -
Shareholding: 20,850 (own and affiliated holdings)
Member of the Board since 2017. Chairman of the Audit Committee.
M.Sc. in Aerospace Engineering and M.Sc. in Business Economics. CEO of SkylineDx and managing director of Exponential B.V. Extensive board experience in life science companies, with previous board assignments in for example Agendia, deVGen, Innate Pharma, Isobionics and Octoplus. Board member of BioInvent during 2013–2016. Currently Fund Manager for Swanbridge Capital. Born 1976.
Other board appointments: Board member of DCPrime, VitalneXt, Ceradis BV and Anemones Hospitality and Hotels.
Elin Jaensson Gyllenbäck
Member of the Board since 2017.
Ph.D. in Immunology. Senior Research Scientist. Born 1979.
Other board appointments: -
An van Es Johansson
Member of the Board since 2016. Member of the Remuneration
M.D. Previously different executive positions in Clinical Development, Medical Affairs, Business Development and Commercial within Swedish Orphan Biovitrum, Eli Lilly, Roche, Pharmacia & Upjohn and biotech companies in USA, the Netherlands, Switzerland and Sweden. Born 1960.
Other board appointments: Board member of Medivir AB, Agendia, Savara Pharmaceutical Inc and PLUS Therapeutics Inc.
Member of the Board since 2016.
CFA, Ph.D. Partner NeoMed Management. Former partner in Private Equity Sectoral Asset Management and Omega Funds. Researcher at University of Geneva. Research analyst at Pictet Bank. Born 1968.
Other board appointments: Board member of Etherna Immunotherapies, FoRx, Immunic and Sophia Genetics.
Member of the Board since 2018. Chairman of the Science Committee, and member of the Remuneration Committee.
Doctor of Medicine and Doctor of Neurobiology. Previous experience as CEO and President of GPC Biotech, Executive Vice President and Chief Scientific Officer at Genome Therapeutics Corporation and Vice President of Oncology Drug Discovery and, in parallel, Vice President of Corporate and Academic Alliances, both at Bristol-Myers Squibb. Senior faculty positions at Harvard Medical School, Massachusetts General Hospital, and Princeton University. Born 1956.
Other board appointments: Board member and chairman of multiple public and private biotech companies in the United States, Europe, and Canada, including Oxford BioTherapeutics, CryptoMedix Inc., Oncolytics Biotech Inc., Aprea AB and Vaccibody AS. Advisory board member/Senior Advisor to Biotech Venture Capital Funds such as BB Pureos Bioventures and Hadean Ventures.